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Background: Whole brain radiotherapy (WBRT) plus sequential focal radiation boost is a commonly used
therapeutic strategy for patients with brain metastases. However, recent reports on WBRT plus simultaneous in-field
boost (SIB) also showed promising outcomes. The objective of present study is to retrospectively evaluate the
efficacy and toxicities of WBRT plus SIB with image guided intensity-modulated radiotherapy (IG-IMRT) for
inoperable brain metastases of NSCLC.
Methods: Twenty-nine NSCLC patients with 87 inoperable brain metastases were included in this retrospective
study. All patients received WBRT at a dose of 40 Gy/20 f, and SIB boost with IG-IMRT at a dose of 20 Gy/5 f concurrent
with WBRT in the fourth week. Prior to each fraction of IG-IMRT boost, on-line positioning verification and correction
were used to ensure that the set-up errors were within 2 mm by cone beam computed tomography in all patients.
Results: The one-year intracranial control rate, local brain failure rate, and distant brain failure rate were 62.9%, 13.8%,
and 19.2%, respectively. The two-year intracranial control rate, local brain failure rate, and distant brain failure rate were
42.5%, 30.9%, and 36.4%, respectively. Both median intracranial progression-free survival and median
survival were 10 months. Six-month, one-year, and two-year survival rates were 65.5%, 41.4%, and 13.8%, corresponding
to 62.1%, 41.4%, and 10.3% of intracranial progression-free survival rates. Patients with Score Index for Radiosurgery in
Brain Metastases (SIR) >5, number of intracranial lesions <3, and history of EGFR-TKI treatment had better survival.
Three lesions (3.45%) demonstrated radiation necrosis after radiotherapy. Grades 2 and 3 cognitive impairment with
grade 2 radiation leukoencephalopathy were observed in 4 (13.8%) and 4 (13.8%) patients. No dosimetric parameters
were found to be associated with these late toxicities. Patients received EGFR-TKI treatment had higher incidence of
grades 2–3 cognitive impairment with grade 2 leukoencephalopathy.
Conclusions: WBRT plus SIB with IG-IMRT is a tolerable and effective treatment for NSCLC patients with inoperable
brain metastases. However, the results of present study need to be examined by the prospective investigations.
Keywords: Whole brain radiotherapy, Simultaneous in-field boost, Brain metastases, Non-small cell lung cancer* Correspondence: radyoulu@hotmail.com
†Equal contributors
1Department of Thoracic Cancer, Cancer Center, West China Hospital of
Sichuan University, Chengdu, Sichuan Province, China
4State Key Laboratory of Biotherapy, West China Hospital of Sichuan
University, Chengdu, Chengdu, Sichuan Province, China
Full list of author information is available at the end of the article
© 2014 Zhou et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Zhou et al. Radiation Oncology 2014, 9:117 Page 2 of 9
http://www.ro-journal.com/content/9/1/117Background
Non-small cell lung cancer (NSCLC) is one of the most
common malignant tumors, and approximately 36%-44%
of patients with NSCLC present with brain metastases
during the course of disease [1]. During the past 50 years,
whole brain radiotherapy (WBRT) has been the standard
treatment for brain metastases, but its therapeutic ef-
fects are suboptimal with intracranial control rate (ICR)
of 60% and median survival of 3–6 months [1,2]. Stereo-
tactic radiosurgery (SRS) is beneficial in patients with
limited number and volume of metastases and it has be-
come increasingly available as an alternative focal treat-
ment to surgery, but its therapeutic effects decrease with
increasing number and volume of lesions [3]. Further-
more, SRS is not recommended in patients with lesions
located in or close to critical anatomic structures because
of unacceptable risk of severe long-term damage [3].
Hypofractionated stereotactic radiotherapy (hfSRT) com-
bines the precise beam delivery of radiosurgical technique
with the radiobiological advantages of fractionation, and
has shown the results comparable to SRS [4].
Noncoplanar arcs, noncoplanar fixed fields and intensity
modulation are the most frequently used stereotactic
radiotherapy techniques. It has been reported that
intensity-modulated radiotherapy (IMRT) technique
results in improved dose conformity as compared to the
other two techniques for the hemisphere and irregular
tumor targets, and may increase the therapeutic ratio of
treating large and/or irregularly shaped intracranial lesions
[5]. Image guided intensity-modulated radiotherapy (IG-
IMRT) is a new technique of radiotherapy. It improves the
accuracy of treatment delivery by using cone beam com-
puted tomography (CBCT) with x-ray volumetric images
(XVI) to give the 3-dimensional anatomic information in
the treatment position and to reduce setup uncertainty
[6]. With these advantages, it is possible to administer
hfSRT with IG-IMRT to brain metastases with non-
invasive head fixation such as thermoplastic mask [6,7].
Several prospective trials proved the superiority of WBRT
plus focal radiotherapy boost in patients with limited
number and volume of brain metastases [8,9], and even in
patients with a large number and volume of brain metas-
tases, several studies indicated that focal hfSRT may be ef-
fective [10,11]. Radiotherapy schedules of most previous
reports were WBRT plus sequential SRS/hfSRT boost.
Recently, some reports showed that WBRT plus simulta-
neous in-field boost (SIB) with helical tomotherapy were
effective and tolerable for brain metastases [12-15]. In our
department, 40 Gy/20 f (5 f/week) used to be the standard
schedule of WBRT, and some NSCLC patients with brain
metastases received SIB with IG-IMRT in the fourth week
of WBRT if they had no or only mild neurological symp-
toms during the first three weeks. Therefore, we conducted
this retrospective study to evaluate the efficacy andtoxicities of WBRT plus SIB with IG-IMRT for NSCLC
patients with brain metastases.
Methods
Clinical information
From July 2006 to April 2009, 29 NSCLC patients with
a total of 87 brain metastases were treated with WBRT
plus SIB with IG-IMRT in our department. All of these
patients had Karnofsky Performance Status (KPS) scores
≥50, and inoperable brain metastases determined by ex-
perienced neurosurgeons. Of these 29 patients, 11 received
epidermal growth factor receptor tyrosine kinase inhibitor
(EGFR-TKI) treatment (9 with gefinitib, 2 with erlotinib)
concurrent with and maintained after radiotherapy.
Detailed patient characteristics are summarized in
Table 1. This retrospective study was approved and go-
verned by the Review Board of West China Hospital
of Sichuan University.
Treatment planning and delivery
All patients received WBRT at a dose of 40 Gy/20 f (5 f/
week), and SIB with IG-IMRT at a dose of 20 Gy/5 f
concurrent with WBRT in the fourth week. Under this
schedule of radiotherapy, intracranial lesions had received
total boost dose of 30 Gy/5 f, and the biological effective
dose (BED) value based on linear-quadratic (LQ) model
(BED = nd [1 + d/(α/β)], α/β = 10 Gy) was close to the SRS
boost of 15-18Gy/1f used to apply in our department. All
patients were immobilized in non-invasive tight thermo-
plastic head masks (Med-Tec, U.S.A) and were treated
by Synergy linear accelerator (Elekta, Sweden) with
6MV X-ray. Helical CT images of 3 mm slice thickness
(Sensation 4, Siemens, Germany) were obtained by
using the Precise Plan System (Version 2.11, Elekta,
Sweden) and were fused with the previously generated
MRI of 3 mm slice thickness (sonata maestro class, Sie-
mens, Germany) by the image fusion system software.
Clinical target volume (CTV) was defined as the whole
brain. Planning target volume (PTV) was defined by
adding a 3D isotropic margin of 5 mm to the CTV ac-
cording to set-up inaccuracy. Gross tumor volume of le-
sion (GTV-L) was defined as the contrast enhancing
tumor on MRI T1 scans. CTV of lesion (CTV-L) was
defined as identical with GTV-L. PTV of lesion (PTV-L)
was defined by adding a 3D isotropic margin of 2 mm to
the GTV-L according to set-up inaccuracy. Inverse co-
planar IMRT planning was used to ensure that 95% of
PTV was covered by 100% isodose envelope of 40 Gy,
and 100% of PTV-L was covered by 100% isodose envelope
of 60 Gy. All patients underwent on-line positioning verifi-
cation and correction to ensure that the set-up errors were
within 2 mm by XVI 3D VolumeView imaging CBCT
(Elekta, Sweden) prior to each IG-IMRT boost. Planning
CT and VolumeView images were registered using
Table 1 Patient characteristics


































<3 cc 12 (41.38)
≥3 cc 17 (58.62)
Total volume of lesions
<7 cc 15 (51.72)
≥7 cc 14 (48.28)
Total 29
Abbreviations: KPS = Karnofsky performance status; RPA = recursive
partitioning analysis; SIR = score index for radiosurgery in brain metastases;
GPA = graded prognostic assessment; EGFR-TKI = epidermal growth factor
receptor tyrosine kinase inhibitor.
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software. Steroids were administered to all patients in
the fourth week of radiotherapy and if patients were
symptomatic in the first three weeks (see Figure 1 for
the treatment schedule). All patients had completed
the treatment successfully.
Follow-up and statistics
All patients were subjected to weekly neurologic exami-
nation during the radiotherapy, and underwent clinical
follow-up examinations including contrast-enhanced MRI
1 month after the end of radiotherapy and every 3 months
thereafter. Response evaluation was based on the World
Health Organization (WHO) criteria, and assessed by
measurement of enhanced lesions in T1-weighted contrast-
enhanced MRI image. ICR was defined as rates of complete
response (CR) plus partial response (PR) and stable disease
(SD) of intracranial lesions. Objective response rate (ORR)
was defined as rates of CR plus PR of intracranial lesions.
Local brain failure rate (LBFR) was defined as rate of
progression of previously treated brain metastases. Re-
gional brain failure rate (RBFR) was defined as rate of
new brain metastases. Overall survival time (OS) was
calculated from the day of starting radiotherapy to the last
day of follow-up or death. The intracranial progression-
free survival (IC-PFS) was calculated from the day of start-
ing radiotherapy to the day of intracranial lesions progres-
sion, death or the last day of follow-up. All side effects
were evaluated according to the National Cancer Institute
Common Terminology Criteria for Adverse Events
(CTCAE) ver. 3.0 grading system. Side effects occur-
ring beyond 90 days from the end of radiotherapy were
considered late toxicities.
The Kaplan-Meier method was used to estimate survival
curve, ICR, LBFR, and RBFR. The Log-rank test was used
for univariate analysis of prognostic factors, and variables
found significant in univariate analysis were further sub-
jected to multivariate Cox-regression. The crosstabs was
used for univariate analysis of the risk factors of late toxic-
ities, and variables found significant in univariate analysis
were further subjected to multivariate binary logistic re-
gression. The independent-samples t-test was used for the
dosimetry analysis. p < 0.05 was regarded as statistically
significant. All calculations were performed by SPSS 17.0.
Results
Local tumor control and survival
The median follow-up time was 10 months (range: 3–48
months), 27.6% (8/29) of patients died within 6 months
after radiotherapy, and 72.4% (21/29) of patients were
followed-up beyond 6 months. Up to the last follow-up
visit, 13 patients had intracranial failure, with 7 new
intracranial metastases and 6 locoregional progression.
The ORR was 69%. The one-year ICR, LBFR, and RBFR
Figure 1 Treatment schedule. All patients received WBRT at a dose of 40 Gy/20 f/4 weeks, and SIB with IG-IMRT at a dose of 20 Gy/5 f concurrent
with WBRT in the fourth week. Steroids (dexamethasone) were administered to all patients in the fourth week of radiotherapy. Abbreviations:
WBRT = whole brain radiotherapy; IG-IMRT = image guided intensity-modulated radiotherapy; treatment delivery.
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ICR, LBFR, and RBFR were 42.5%, 30.9%, and 36.4%, re-
spectively. Twenty-one patients died due to extracranial
failure and 8 died due to intracranial failure. The OS of
whole patients ranged from 3 to 48 months, and the
median survival (MS) was 10 months (95% CI: 5.6-
14.4 months). The six-month, one-year, and two-year
survival rates were 65.5%, 41.4%, and 13.8%, respectively
(Figure 2). The IC-PFS of whole patients ranged from 1
to 43 months, and the median IC-PFS was 10 months
(95% CI: 4.7-15.3 months). The six-month, one-year,
and two-year IC-PFS rates were 62.1%, 41.4%, and
10.3%, respectively (Figure 3).In univariate analysis, fe-
male, adenocarcinoma, Score Index for Radiosurgery in
Brain Metastases (SIR) score >5, number of intracranial
lesions <3, total volume of intracranial lesions <7 cc,
and history of EGFR-TKI treatment were significant
predictors for better OS and IC-PFS(see Table 2). InFigure 2 Overall survival of the whole patients. The Kaplan-Meier overa
two-year survival rates were 65.5%, 41.4% and 13.8%, respectively.multivariate analysis, SIR score >5, number of intracranial
lesions <3, and history of EGFR-TKI treatment remained
significant as favorable prognostic factors (see Table 2).
Toxicities
The radiation-induced acute toxicities were generally mild
(grades 1–2). The most frequent toxicities were grade 2
alopecia (reported in 29 patients, 100%), grade 1 radiation
dermatitis (reported in 29 patients, 100%), grades 1–2
headache (reported in 8 patients, 27.6%), and grades 1–2
nausea (reported in 5 patients, 17.2%). There were no
grade 3 acute toxicities.
The radiation-induced late toxicities were reported in
25 patients, including grades 1 and 2 leukoencephalopathy
in 17 (58.6%) and 8 (27.6%) patients, respectively; grades
1, 2, and 3 cognitive disturbance in 6 (20.7%), 4 (13.8%),
and 4 (13.8%) patients, respectively. All patients with
grade 2 or 3 cognitive impairment also had grade 2ll survival curve of whole group showed the six-month, one-year and
Figure 3 IC-PFS of the whole patients. The Kaplan-Meier IC-PFS curve of whole group showed the six-month, one-year and two-year IC-PFS
rates were 62.1%, 41.4% and 10.3%, respectively. Abbreviations: IC-PFS = intracranial progression-free survival.
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2 (6.90%) different patients demonstrated radiation necrosis
after radiotherapy. In univariate analysis, female, age ≥
60 year-old, and history of EGFR-TKI treatment were
risk factors for grade 2 leukoencephalopathy, and only
history of EGFR-TKI treatment remained statistically
significant in multivariate analysis (see Table 2). The time
from radiotherapy to the occurrence of grade 2 or 3 cogni-
tive impairment was 2–24 months with the median time
of 9 months. The time from radiotherapy to the occur-
rence of grade 1 or 2 radiation leukoencephalopathy was
2–9 months with the median time of 6 months.
Dosimetry
The median GTV of individual lesions were 6.62 cc
(range: 2.41 cc-70.74 cc), and the median whole brain vol-
ume were1420.9 cc (range: 1215.2 cc-1587.5 cc). At the
time of IG-IMRT boost, some region of normal brain tis-
sue would have received more than 3-5 Gy/f. VXG was
defined as volume of normal brain tissue receiving at least
XGy per fraction during the SIB, and the V3G, V4G, and
V5G in present study ranged from 47.90 cc to 474.30 cc,
15.40 cc to 241.26 cc, and 8.36 cc to 128.30 cc, respect-
ively. VX was defined as the percentage volume of normal
brain receiving at least XGy per fraction during the SIB.
The V3, V4, and V5 in present study ranged from 1.11%
to 10.87%, 0.37% to 5.46%, and 0.20% to 2.98%, respect-
ively. In the dosimetry analysis, there was no correlation
between the incidence of grade 2 leukoencephalopathy
and V3G-V5G or V3-V5 (see Table 3). However, number
of intracranial lesions >3, maximum intracranial lesionvolume ≥3 cc, and total volume of intracranial lesions
≥7 cc were statistically significant associated with larger
V3G-V5G and V3-V5 (see Table 3).
Discussion
WBRT plus sequential focal SRS/hfSRT boost is one of the
most widely used therapeutic strategies for patients with
limited brain metastases. However, evidence on efficacy and
toxicities of WBRT plus simultaneous hfSRT are emerging
recently. The phase I trial of WBRT plus SIB with helical
tomotherapy showed that the delivery of 60 Gy/10 f syn-
chronously with WBRT of 30 Gy was tolerable in patients
with 1–3 brain metastases, and the Phase II trial is ongoing
to examine its efficacy [12,13]. Just like helical tomotherapy,
the Synergy IGRT system used in our study is one of
integrated image-guided intensity-modulated-capable
radiotherapy platforms. However, different from the more
advanced arc-based IMRT such as helical tomotherapy,
the radiation technology used in our study was a step-
and-shoot IMRT which was more common and econom-
ically feasible in developing countries. Furthermore, only
NSCLC patients were eligible in our study, and they were
more homogeneous with respect to previous reports of
WBRT plus SIB with helical tomotherapy, which en-
rolled patients without prescribing a limit to pathological
type of primary cancer [12-14].
The reported one-year ICR and median survivals of pa-
tients with limited brain metastases received WBRT plus
sequential focal hfSRT boost were 66%-86% and 7.5-13
months [16-20]. Unlike reports above, approximately half
of patients in our study had multiple (≥3) or large (≥3 cc)




















Male 6 0.020 0.869 7 0.019 0.983 3/20 (15.5) 0.024 0.562
Female 18 18 5/9 (55.6%)
Age (years)
≥60 8 0.628 8 0.719 5/18 (27.8) 0.794
<60 12 12 3/11 (27.3)
KPS scores
≥70 12 0.251 12 0.223 5/19 (26.3) 0.833
<70 3 4.4 3/10(30)
Pathology
Adenocarcinoma 14 0.015 0.519 14 0.011 0.553 6/13 (46.2) 0.044 0.084
Non-adenocarcinoma 3 4.4 2/16 (12.5)
RPA class
2 12 0.266 12 0.185 5/19 (26.3) 0.833
3 3 4.4 3/10 (30.0%)
GPA scores
0-1 6 0.331 7 0.188 4/13 (30.8) 0.730
1.5-3.5 14 14 4/16 (25%)
SIR scores
≤5 3 0.001 0.044 4.4 <0.001 0.021 5/13 (38.5) 0.238
>5 14 14 3/16 (18.75)
History of EGFR-TKI
treatment
Yes 16 0.026 0.035 18 0.022 0.040 7/11 (63.6) 0.001 0.010
No 6 7 1/18 (5.6)
Number of lesions
<3 14 0.005 0.036 14 0.007 0.048 6/15 (40.0) 0.122
≥3 3 6 2/14 (14.3)
Maximum lesion
volume
<3 cc 14 0.209 14 0.081 4/12 (33.3) 0.561
≥3 cc 4.4 6 4/17 (23.5)
Total volume of lesions
<7 cc 14 0.032 0.232 14 0.037 0.256 5/15 (33.3) 0.474
≥7 cc 3 6 3/14 (21.4)
Total 10 10 8/29 (27.6)
Abbreviations: IC-PFS = intracranial progression-free survival; MS =median survival; m =month; RPA = recursive partitioning analysis; GPA = graded prognostic
assessment; SIR = score index for radiosurgery in brain metastases; EGFR-TKI = epidermal growth factor receptor- tyrosine kinase inhibitor.
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studies. However, the median survival and one-year ICR
of whole patients in our study were 10 months and 62.9%,
which were close to previous data in above studies. Several
grading systems are available for brain metastases, such as
Graded Prognostic Assessment (GPA), Recursive Parti-
tioning Analysis (RPA) and SIR. Higher level of RPA andlower scores of GPA and SIR are associated with worse
survival of patients with brain metastases [21-24]. Simi-
larly, the survival was better in RPA class II, GPA scores
1.5-3.5, and SIR >5 patients in our study. However, pos-
sibly because of the limited number of enrolled patients,
only differences in survivals between patients with SIR ≤5
and >5 were statistically significant. The number of lesions
Table 3 Univariateanalysis of V3G-V5G and V3-V5
V3G (cc) V4G (cc) V5G (cc) V3 (%) V4 (%) V5 (%)
Mean ± SD p Mean ± SD p Mean ± SD p Mean ± SD p Mean ± SD p Mean ± SD p
leukoencephalopathy
Grade 0-1 204.94 ± 150.85 0.288 77.94 ± 67.47 0.316 34.12 ± 30.99 0.574 4.66 ± 3.40 0.102 1.77 ± 1.52 0.334 0.78 ± 0.71 0.609
Grade 2 128.60 ± 80.62 51.08 ± 49.53 27.14 ± 24.85 3.00 ± 1.81 1.18 ± 1.12 0.63 ± 0.57
Number of lesions
<3 126.05 ± 115.60 0.017 39.06 ± 44.83 0.004 18.65 ± 17.00 0.010 2.94 ± 2.55 0.020 0.91 ± 0.98 0.004 0.44 ± 0.39 0.013
≥3 245.84 ± 136.82 104.24 ± 64.15 46.70 ± 32.90 5.57 ± 3.14 2.36 ± 1.47 1.05 ± 0.76
Maximum lesion
volume
<3 cc 94.13 ± 67.73 0.004 35.77 ± 27.52 0.006 15.35 ± 7.55 0.003 2.20 ± 1.42 0.001 0.83 ± 0.61 0.006 0.36 ± 0.17 0.004
≥3 cc 238.73 ± 143.95 91.77 ± 70.05 42.49 ± 32.74 5.43 ± 3.24 2.08 ± 1.58 0.97 ± 0.75
Total volume
of lesions
<7 cc 108.74 ± 76.57 0.002 35.82 ± 31.48 0.002 15.43 ± 11.06 0.001 2.55 ± 1.75 0.003 0.83 ± 0.70 0.002 0.36 ± 0.25 0.002
≥7 cc 264.39 ± 145.93 107.71 ± 68.56 50.15 ± 30.07 5.98 ± 3.30 2.44 ± 1.56 1.14 ± 0.74
Total 183.87 ± 138.15 70.53 ± 63.36 32.19 ± 29.16 4.21 ± 3.10 1.61 ± 1.43 0.74 ± 0.67
Abbreviations: VXG =. The volume of normal brain tissue receiving at least XGy per fraction during the SIB; VX =. The percentage volume of normal brain
receiving at least XGy per fraction during the SIB; cc = cubic centimeter.
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and patients with limited number of brain metastases
seem to have better outcomes. It has been reported that
median survivals were 6.5-16 months following WBRT
plus focal radiotherapy boost in patients with single intra-
cranial lesion, corresponding to 5.8-13months in patients
with multiple intracranial lesions [8,9,16,17]. Similarly, pa-
tients with number of lesions <3 showed better outcomes
in our study, and the median survival was comparable to
the data reported by other investigators [11,17,20].
Several studies showed that the radiosensitivity of brain
metastases is associated with the mutation status of epi-
dermal growth factor receptor (EGFR) [25-27]. Compared
to patients with the wild-type, those with activating EGFR
mutations had higher response rates and better survival
following WBRT (54% VS. 24%, P = 0.045; 17.3 months
VS. 6.6 months, P = 0.121) [26]. EGFR-TKI, either alone
or combined with WBRT, is effective in brain metasta-
ses of NSCLC especially for EGFR-mutated patients
[26,28,29]. From the phase I and II trials of WBRT with
concurrent and maintenance erlotinib in NSCLC with
brain metastases, erlotinib in combination with WBRT
was well tolerated and had a favorable efficacy. More-
over, EGFR-mutated patients had a better survival
compared to those with wild-type (median survival:
19.1 months VS. 9.3 months) [29,30]. In present study,
history of EGFR-TKI treatment was also a favorable
prognostic factor for survival, and the median survival
of 11 patients received concurrent and maintenance
EGFR-TKI treatment was as long as 18 months. EGFR
mutation status is not available in our study. However,
most patients who received EGFR-TKI in this studywere female (72.7%) and had adenocarcinoma (81.8%).
Considering the evidence that Asian, female, non-
smoking, and adenocarcinoma patients were more likely
to be EGFR mutated, and rates of EGFR mutation in brain
metastases of NSCLC were 44%-63% in East Asian popu-
lation [31,32]. We speculated that EGFR mutations might
contribute to the better survival in the EGFR-TKI treated
patients in present study.
Considering the concurrent WBRT, intracranial lesions
received total boost doses of 30 Gy/5 f in our study. By
using the α/β ratio of 12 Gy and LQC model (BED = nd
[1 + d/(α/β)-d2/(α/γ)]), which was indicated to be suitable
for calculating BED value of SRS or hfSRT for brain me-
tastases [33], the BED value of total boost were 43.33 Gy,
which was comparable to other reports of brain metasta-
ses treated by hfSRT [12,13,16-20,34]. Late radiation tox-
icity of 13.8% grade 3 cognitive impairment in our group
was comparable to previous data of 6%-11% grade 3 late
toxicities from other studies [16,17]. The incidence of
radiation necrosis was one of the major concerns in late
toxicities from WBRT plus focal radiotherapy boost, but
it was quite infrequent in our study, and was similar to
other reports of WBRT plus focal hfSRT boost [10,16-18].
Leukoencephalopathy and cognitive impairment were
primary late toxicities in present study, and only history
of EGFR-TKI treatment was a risk factor for grade 2
leukoencephalopathy in multivariate analysis, which
had not been reported by other studies. Patients who
received EGFR-TKI treatment had the longer survival,
which might partly explain the higher incidence of late
toxicities in these patients. It has been reported that the
EGFR-TKI plus concomitant WBRT may have synergy
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and IC-PFS were significantly higher in gefitinib plus
WBRT compared with gefitinib alone (ORR: 64.4% VS.
26.7%, P < 0.001; DCR: 71.1% VS. 42.2%, P = 0.006; IC-
PFS: 10.6 months VS. 6.57 months, P < 0.001) [35]. It is a
reasonable assumption that the EGFR-TKI plus con-
comitant brain radiotherapy might also have synergy
neurotoxicity, and it might be another reason for the
higher incidence of late toxicities in patients with EGFR-
TKI treatment. However, considering the limited number
of patients in our study, it may need more preclinical and
clinical data to support this assumption.
This retrospective study had many limitations such as
heterogeneity and limited number of enrolled patients,
lack of phase I data, lack of health-related quality of life
(HRQoL) data, and lack of neurocognative testing data.
We look forward to that the ongoing phase II trial of
SIB with helical tomotherapy for 1–3 brain metastases
will give us more information [13].
Conclusions
WBRT plus SIB with IG-IMRT is a tolerable and effect-
ive treatment for NSCLC patients with inoperable brain
metastases, especially for those with SIR score >5, num-
ber of intracranial lesions <3, and history of EGFR-TKI
treatment. However, the results of present study need to
be examined by the prospective investigations.
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